SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Extending the Reach: Long-Acting Antiviral and Novel Delivery
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
10 of
10
|
Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI (ABSTRACT
174)
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing (ABSTRACT
175)
Nilay Thakkar
GSK plc, Collegeville, PA, USA
Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184 (ABSTRACT
176)
Hyunmoon Back
GSK plc, Collegeville, PA, USA
DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study (ABSTRACT
177)
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
Questions and Answers (Part 1)
Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study (ABSTRACT
178)
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial (ABSTRACT
179)
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks (ABSTRACT
180)
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1 (ABSTRACT
181)
Chloe M. Orkin
Queen Mary University of London, London, UK
Questions and Answers (Part 2)
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
10 of
10
|
